Fig. 3From: Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST studyPercentage of patients with ≥ 50%, ≥ 75%, and 100% reductions in monthly migraine headache days at month 3 (end of double-blind period) and month 6 (end of open-label period)DB, double-blind; GMB, galcanezumab; OL, open-label; PBO, placebo; SE, standard error*p < 0.05 versus placebo; ***p < 0.0001 versus placeboBack to article page